Connect to other sites within the UBM Medica Network
Protein in Ovarian Cancers Deactivates Immune System Response
Ovarian cancer progression may be driven by the activation of an endoplasmic reticulum stress response factor that disrupts the function of dendritic cells and, subsequently, antitumor fighting T cells.
CONSIGN, CONCUR Confirm Efficacy of Regorafenib in mCRC
Two phase III trials have confirmed the benefit of regorafenib, an oral multikinase inhibitor, in patients with previously treated metastatic colorectal cancer.
TAS-102 Effective for Wild-Type, Mutant KRAS mCRC
A subgroup analysis of the phase III RECOURSE trial has shown that TAS-102 is effective at improving survival in patients with both KRAS wild-type or mutant metastatic colorectal cancer.
FOLFOX/Cetuximab Prolonged Survival in Mutation-Free Colorectal Cancer
Treatment with FOLFOX plus cetuximab resulted in improved PFS vs FOLFOX alone in patients with metastatic colorectal cancer with “all-RAS” wild-type tumors.
Post-Op RT Improves Survival in Incompletely Resected NSCLC
Use of post-operative radiotherapy was associated with better overall survival in patients with incompletely resected stage II/III non-small-cell lung cancer.
Doublets Match Triplet Regimens in Transplant-Ineligible Myeloma
Use of a VD regimen alone to treat patients with transplant-ineligible multiple myeloma was not inferior to VTD or VMP regimens, according to the UPFRONT trial.
Majority of Lung, Colorectal Cancer Patients Believe Surgery Curative
Large proportions of lung and colorectal cancer patients believe that surgery will cure their cancer, according to results of a new population-based study.
Ibrutinib Improves on Standard of Care in CLL/SLL
A trial found that ibrutinib in combination with bendamustine and rituximab is superior to standard of care in patients with previously treated CLL/SLL.
Adjuvant Chemo Ups Survival in High-Risk Localized Prostate Cancer
The addition of docetaxel and prednisone to standard therapy may be the first effective adjuvant chemotherapy treatment for high-risk prostate cancer patients.
Palbociclib, Fulvestrant Delays HR-Positive Breast Cancer Progression
The addition of palbociclib to fulvestrant delayed disease progression in women with HR-positive, HER2-negative metastatic breast cancer.
Anastrozole Trumps Tamoxifen in DCIS
Treatment of postmenopausal DCIS patients with the aromatase inhibitor anastrozole resulted in higher breast cancer–free survival rates compared with treatment with tamoxifen.
By clicking Accept, you agree to become a member of the UBM Medica Community.